Cresco Labs reported Q2 2024 revenue of $184.356 million, delivering a meaningful margin expansion and solid free cash flow generation as the company executes on its three strategic pillars: strategic footprint optimization (notably Ohio, Pennsylvania and Florida), leadership in branded wholesale, and a productive retail portfolio. Management emphasized a disciplined focus on margins and free cash flow as the backbone for sustainable growth, with adjusted gross margins around 52% and adjusted EBITDA of $54 million (up $13 million YoY). The quarter featured notable operating momentum in Ohio (early AU launch with a favorable yield and potency uplift) and continued progress in Florida, plus selective acquisitions in Pennsylvania to broaden Sunnyside's footprint. Management also underscored a capital-efficient plan to grow capacity while targeting a gross margin around 50% for 2024, and highlighted a tax strategy expected to deliver meaningful cash tax savings. The market remains sensitive to legislative timing (e.g., rescheduling discussions and AU rules in Ohio slated for fall) and to state-level pricing dynamics, which Creco feels can be managed through ongoing operational improvements and capital discipline. The combination of margin discipline, improving cash flow, and a growing, strategically positioned footprint suggests Cresco is positioned to drive profitable growth through 2025–2026, contingent on favorable regulatory progress and continued operating leverage across its footprint.